A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma
Clinical trial NCT03593109 · TERMINATED
Trial details
- NCT number
- NCT03593109
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-30
- Primary completion
- 2021-05-01
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.